Related Experiment Video

Updated: Jun 1, 2026

Bladder Smooth Muscle Strip Contractility as a Method to Evaluate Lower Urinary Tract Pharmacology
10:26

Bladder Smooth Muscle Strip Contractility as a Method to Evaluate Lower Urinary Tract Pharmacology

Published on: August 18, 2014

Cardiac effects of muscarinic receptor antagonists used for voiding dysfunction

Karl-Erik Andersson1, Lysanne Campeau, Brian Olshansky

  • 1Wake Forest Institute for Regenerative Medicine,Wake Forest University School of Medicine, Medical Center Boulevard, Winston Salem, NC 27157, USA. karl-erik.andersson@med.lu.se

British Journal of Clinical Pharmacology
|May 21, 2011
PubMed

Insights

Antimuscarinic drugs for overactive bladder may cause serious cardiac side effects like increased heart rate and QT prolongation. More research is needed to assess these risks across different antimuscarinic agents.

Area of Science:

  • Pharmacology
  • Cardiology
  • Urology

Background:

  • Overactive bladder (OAB) is a chronic condition often treated with antimuscarinic agents.
  • Antimuscarinics are generally safe but carry cardiac risks, including increased heart rate (HR) and QT prolongation.
  • Elevated HR is linked to increased morbidity and mortality, especially in cardiovascular patients.

Purpose of the Study:

  • To review the cardiac adverse effects of antimuscarinic agents used for OAB.
  • To explore the potential for differences in cardiac risk among various antimuscarinic drugs.
  • To highlight the need for better risk assessment of these widely used medications.

Main Methods:

  • Literature review of antimuscarinic agents and their cardiac effects.
  • Analysis of reported cases and studies on HR and QT interval changes.
  • Evaluation of the mechanism of cardiac side effects, including hERG channel inhibition.

Main Results:

  • Antimuscarinics can increase HR and prolong the QT interval, potentially leading to torsade de pointes.
  • QT prolongation is linked to hERG channel inhibition, not muscarinic receptor blockade.
  • Limited data exists on the comparative cardiac risks of different antimuscarinic drugs.

Conclusions:

  • Antimuscarinic therapy for OAB requires careful cardiac monitoring.
  • Further research is essential to differentiate the cardiac safety profiles of individual antimuscarinic agents.
  • Informed risk-benefit assessments are currently challenging due to insufficient comparative data.

More Related Videos

The Use of Cystometry in Small Rodents: A Study of Bladder Chemosensation08:08

The Use of Cystometry in Small Rodents: A Study of Bladder Chemosensation

Published on: August 21, 2012

Preparation and Utilization of Freshly Isolated Human Detrusor Smooth Muscle Cells for Characterization of 9-Phenanthrol-Sensitive Cation Currents08:30

Preparation and Utilization of Freshly Isolated Human Detrusor Smooth Muscle Cells for Characterization of 9-Phenanthrol-Sensitive Cation Currents

Published on: January 31, 2020

Related Concept Videos

Cholinergic Antagonists: Pharmacological Actions01:28

Cholinergic Antagonists: Pharmacological Actions

Antimuscarinic drugs block muscarinic receptors in multiple systems, including the gut, eye, smooth muscles, respiratory tract, cardiovascular, and central nervous systems. They produce similar effects with varying selectivity depending on the specific agent and tissue. Here are the key pharmacological actions of antimuscarinics:
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
Cholinergic Antagonists: Therapeutic Uses01:26

Cholinergic Antagonists: Therapeutic Uses

Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:    
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal secretions in common...
Antiasthma Drugs: Muscarinic Receptor Antagonists01:20

Antiasthma Drugs: Muscarinic Receptor Antagonists

Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
Direct-Acting Cholinergic Agonists: Pharmacological Actions00:59

Direct-Acting Cholinergic Agonists: Pharmacological Actions

Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...
Direct-Acting Cholinergic Agonists: Therapeutic Uses01:11

Direct-Acting Cholinergic Agonists: Therapeutic Uses

Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren syndrome.
Cholinergic Antagonists: Pharmacokinetics01:24

Cholinergic Antagonists: Pharmacokinetics

Cholinergic antagonists—such as antimuscarinics—are available in oral, topical, ocular, parenteral, and inhalational formulations. Most antimuscarinics are oral formulations,  while scopolamine is available as a topical patch, and ipratropium and tiotropium are available as inhalation aerosols or powders. Atropine, tropicamide, and cyclopentolate are topically instilled in the eye. Most antimuscarinics are lipid-soluble and readily absorbed from the gastrointestinal tract and the conjunctiva.